<?xml version="1.0" encoding="UTF-8" ?>
<!-- Created from PDF via Acrobat SaveAsXML -->
<!-- Mapping Table version: 28-February-2003 -->
<TaggedPDF-doc>
<?xpacket begin='﻿' id='W5M0MpCehiHzreSzNTczkc9d'?>
<?xpacket begin="﻿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.0-c000 79.cca54b0, 2022/11/26-09:29:55        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmp:CreateDate>2023-03-10T19:36:39Z</xmp:CreateDate>
         <xmp:CreatorTool>wkhtmltopdf 0.12.5</xmp:CreatorTool>
         <xmp:ModifyDate>2023-03-30T13:28:55-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2023-03-30T13:28:55-04:00</xmp:MetadataDate>
         <pdf:Producer>Qt 4.8.7</pdf:Producer>
         <dc:format>xml</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">RPT28095</rdf:li>
            </rdf:Alt>
         </dc:title>
         <xmpMM:DocumentID>uuid:9fafbbc6-3790-45bc-9de0-eb51c0fc69d9</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:2ddd30d3-9304-4d5d-bd8d-185149b4cac4</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>
<?xpacket end='r'?>
<bookmark-tree>
<bookmark title="Diagnostic Genomics Laboratory">
<destination structID="LinkTarget_98"/>
</bookmark>
<bookmark title="03/10/2023">
<destination structID="LinkTarget_98"/>
</bookmark>
<bookmark title="Plasma Cell Myeloma Panel">
<destination structID="LinkTarget_99"/>
<bookmark title="Method">
<destination structID="LinkTarget_100"/>
</bookmark>
<bookmark title="Limitations:">
<destination structID="LinkTarget_101"/>
</bookmark>
<bookmark title="Disclaimer:">
<destination structID="LinkTarget_102"/>
</bookmark>
<bookmark title="Plasma Cell Myeloma Gene Sequencing Panel">
<destination structID="LinkTarget_103"/>
</bookmark>
<bookmark title="Copy number variants">
<destination structID="LinkTarget_104"/>
</bookmark>
<bookmark title="Translocations">
<destination structID="LinkTarget_105"/>
</bookmark>
</bookmark>
</bookmark-tree>
<Figure>

<ImageData src="images/RPT28095_img_0.jpg"/>
</Figure>

<Part>
<H5 id="LinkTarget_98">Diagnostic Genomics Laboratory 03/10/2023 </H5>

<Sect>
<H5>Ordered By </H5>

<Sect>
<H5>Physician Name: Abonour, Rafat Reason for Referral: Myeloma </H5>

<P>Patient Name: Fankhauser, xxx Accession #: R31516 Specimen #: 31792303725 Birthdate: xx/xx/xxxx Specimen: Bone Marrow Age: xx</P>

<P>Gender: F/M </P>
</Sect>
</Sect>

<Sect>
<H5>MRN #: xxxxxxx Collected: 02/13/2023 Received: 02/14/2023 </H5>

<P id="LinkTarget_99">Plasma Cell Myeloma Panel </P>

<Sect>
<H6>PCM Result: See PDF </H6>

<Table>
<TR>
<TH>Gene (Chr. Position, hg38) </TH>

<TH>Alt. Type </TH>

<TH>Alt. Description </TH>

<TH/>

<TH>Variant Allele Fraction (VAF) </TH>

<TH>Clinical Information </TH>
</TR>

<TR>
<TD>IGH-PPCDC (chr14:105609762;chr15:75066286) </TD>

<TD>Translocation </TD>

<TD>t(14;15) (IGH;PPCDC) </TD>

<TD/>

<TD>17.6% </TD>

<TD>VUS </TD>
</TR>

<TR>
<TD>Chr 3, 5, 7, 9, 11, 15, 17, 19, and 20 </TD>

<TD>Hyperdiploidy </TD>

<TD>Trisomies </TD>

<TD/>

<TD>N/A </TD>

<TD>Pathogenic </TD>
</TR>

<TR>
<TD>CDKN2C (chr1:50970354_50970512) </TD>

<TD>CNV </TD>

<TD>Het. Loss </TD>

<TD/>

<TD>N/A </TD>

<TD>Pathogenic </TD>
</TR>

<TR>
<TD>CKS1B (chr1:154978700_154978800) </TD>

<TD>CNV </TD>

<TD>1-copy gain </TD>

<TD/>

<TD>N/A </TD>

<TD>Pathogenic </TD>
</TR>

<TR>
<TD>NRAS (chr1:114713909 G&gt;T) </TD>

<TD>Missense </TD>

<TD>c.181C&gt;A (Gln61Lys) </TD>

<TD>p. </TD>

<TD>45.5% </TD>

<TD>Pathogenic </TD>
</TR>

<TR>
<TD>CDKN2C (chr1:50970412 G&gt;-) </TD>

<TD>Frameshift </TD>

<TD>c.49delG p.(Asp17Thrfs*2) </TD>

<TD/>

<TD>96.9% </TD>

<TD>Pathogenic </TD>
</TR>

<TR>
<TD>TENT5C (chr1:117623033 C&gt;-) </TD>

<TD>Frameshift </TD>

<TD>c.166delC (Arg56Alafs*16) </TD>

<TD>p. </TD>

<TD>43.6% </TD>

<TD>Pathogenic </TD>
</TR>

<TR>
<TD>TENT5C (chr1:117623064 -&gt;GT) </TD>

<TD>Frameshift </TD>

<TD>c.197_198dupTG (His67Cysfs*6) </TD>

<TD>p. </TD>

<TD>48.7% </TD>

<TD>Pathogenic </TD>
</TR>

<TR>
<TD>LRP1B (chr2:140716763 T&gt;G) </TD>

<TD>Missense </TD>

<TD>c.5812A&gt;C (Lys1938Gln) </TD>

<TD>p. </TD>

<TD>48.9% </TD>

<TD>VUS </TD>
</TR>
</Table>
</Sect>

<Sect>
<H6>INTERPRETATION </H6>

<P>Translocation: Uncertain clinical significance seq [GRCh38] t(14;15) (q32;q24) The translocation t(14;15) detected in this tumor specimen is between the IGH locus (14q32) and the genomic region downstream of PPCDC on (15q24) at genomic location 15:75066286 (hg38). This translocation may juxtapose the IGH locus to the PPCDC gene resulting in dysregulation of gene expression. PPCDC encodes a phosphopantothenoylcysteine decarboxylase enzyme, that is essential in the biosynthesis of coenzyme A (1). Based on the currently available information, the clinical significance of t(14;15) is unknown. </P>

<Sect>
<H6>Hyperdiploidy</H6>

<P>This test detected trisomies of chromosomes 3, 5, 7, 9, 11, 15, 17, 19, and 20 in this tumor specimen. This result is consistent with hyperdiploidy, which is characterized by trisomies involving at least two odd chromosomes particularly chromosomes 3, 5, 7, 9, 11, 15, 17, and 19 (2,3). Hyperdiploidy is one of the genetic abnormalities of PCM that has been observed in approximately 40-50% of the patients and is considered as a favorable prognostic factor. However, the existence of IGH translocations with hyperdiploidy may negatively affect prognostic impact (2). </P>

<P>IU Diagnostic Genomics Laboratory</P>
</Sect>

<Sect>
<H6>Copy Number Variants (CNV) </H6>

<P>This test detected 2 relevant CNVs affecting CDKN2C and CKS1B (see below) </P>

<P>CDKN2C: This test detected a pathogenic one copy loss (heterozygous deletion) of the CDKN2C gene on chromosome 1p32.3 in this tumor specimen. Loss of chromosome 1p32.3/CDKN2C are observed in ~7-40% of patients with PCM (4). CDKN2C is a cyclin-dependent kinase inhibitor known to affect cell-cycle regulation. Deletions of CDKN2C are associated with decreased CDKN2C expression levels and increased proliferation (5). Additionally, a pathogenic hemizygous frameshift variant, c.49delG p.(Asp17Thrfs*2), was detected in CDKN2C in combination with the CDKN2C gene deletion (see interpretation below). Heterozygous or homozygous deletions of CDKN2C are associated with unfavorable prognosis, however; patients with homozygous deletions at 1p32.3, containing CDKN2C, or bi-allelic inactivation of CDKN2C had the most proliferative myelomas (4-7). </P>

<P>CKS1B: This test detected a pathogenic one copy gain (amplification) of the CSK1B gene on chromosome 1q21 in this tumor specimen. Gains or amplification of chromosome 1q21/CKS1B are observed in ~40–45% of patients with PCM, resulting in disruption of the cyclin-dependent kinase regulatory subunit 1B (CKS1B). Although the prognostic impact effect of 1q21/CKS1B gain or amplification is somewhat controversial, the Mayo Clinic model lists CKS1B gain/amp as one of the high-risk factor in PCM (8). Additionally, it has been reported in a study on 132 myeloma patients, that the prognostic impact of CKS1B gain/amplification depends on the background karyotype and TP53 status (9). </P>
</Sect>

<Sect>
<H6>Single Nucleotide Variants (SNVs) </H6>

<P>This test detected 5 SNVs in 4 different cancer-related genes NRAS, CDKN2C, TENT5C, and LRP1B (see below) </P>

<P>NRAS: NM_002524.5(NRAS):c.181C&gt;A p.(Gln61Lys) A missense variant (c.181C&gt;A) in exon 3 that results in the alteration of the codon at amino acid position 61 from glutamine to lysine p.(Gln61Lys) was detected in this tumor specimen. NRAS is one of the most commonly mutated driver gene in plasma cell myeloma (18%) (10-13). Activating NRAS mutations at Gly12, Gly13 or Gln61 cause Ras to accumulate in the active GTP bound state by impairing intrinsic GTPase activity and conferring resistance to GTPase activating proteins (14). This variant has not been observed in a large population cohort (gnomADv3.1.2; https://gnomad.broadinstitute.org). However, this variant was reported as pathogenic in multiple independent plasma cell myeloma tumor samples (15-18; COSMIC ID: COSM580, https://cancer.sanger.ac.uk/cosmic/mutation/overview?id=110462573; ClinVar accession: VCV000073058.16). Based on the currently available information, this variant has been classified as pathogenic. </P>

<P>CDKN2C: NM_078626.3(CDKN2C):c.49delG p.(Asp17Thrfs*2)A hemizygous frameshift variant (c.49delG) in exon 1 of 2 which is expected to cause a premature stop codon at 2 residues downstream of the frame shifted sequence p.(Asp17Thrfs*2) was detected in this tumor specimen. CDKN2C is a cyclin-dependent kinase inhibitor known to affect cell-cycle regulation. Deletions of CDKN2C are associated with decreased CDKN2C expression levels and increased proliferation (19). Hemizygous or homozygous deletions of CDKN2C are associated with unfavorable prognosis, however patients with homozygous deletions at 1p32.3, containing CDKN2C, had the most proliferative myelomas (4-7). Hemizygous loss of function variants including frameshift have been reported in compound heterozygous state with CDKN2C full gene copy-loss (20) or in homozygous state (21; COSMIC ID: COSM2192270). The c.49delG p.(Asp17Thrfs*2) variant has not been observed in a large population cohort (gnomADv3.1.2; https://gnomad.broadinstitute.org) or in ClinVar. However, this variant was reported as pathogenic in one large intestine tumor sample (22; COSMIC ID: COSM2192268,https://cancer.sanger.ac.uk/cosmic/mutation/overview?id=102072881). The hemizygous c.49delG frameshift variant is predicted to cause loss of normal protein function through non-sense mediated mRNA decay or protein truncation. Based on the currently available information, this variant has been classified as pathogenic. </P>

<P>TENT5C (FAM46C): NM_017709.4(TENT5C):c.166delC p.(Arg56Alafs*16) AND c.197_198dupTG p.(His67Cysfs*6) Compound heterozygous (occur on alternate alleles) frameshift variants c.166delC p.(Arg56Alafs*16) and c.197_198dupTG p.(His67Cysfs*6) have been detected in this tumor specimen. TENT5C (Terminal Nucleotidyltransferase 5C), also known as FAM46C, is a non-canonical polyadenylation RNA polymerase that promotes gene expression by enhancing mRNA stability. Loss-of-function variants or deletions in TENT5C are among the most common genetic alterations in plasma cell myeloma, suggesting a function as a tumor suppressor gene (23). TENT5C downregulation because of del(1p12), SNV, or both, has been reported to confer resistance to dexamethasone and lenalidomide in vitro (24). TENT5C is found mutated in 10% of PCM cases, associated with impaired overall survival in the intensive treatment setting (23,24). Similar truncating variants have been reported in PCM [(c.164del) p.V55Afs*17, COSM9361342; (c.299del) p.P100Qfs*18, COSM9511428; (c.358del) p.L120Cfs*5, COSM9511421; https://cancer.sanger.ac.uk/cosmic/gene/samples?all_data=&amp;coords=AA%3AAA&amp;dr=&amp;end=392&amp;gd=&amp;id=323157&amp;ln=TENT5C&amp;mut=deletion_frameshift&amp;seqlen=392&amp;src=gene&amp;start=1]. These compound heterozygous frameshift variants are predicted to escape non-sense mediated mRNA decay predicted to generate a truncated product lacking more than 80% of the protein. The exact functional impact of these removed amino acids is unknown at this time; however, the same alteration and additional truncating alterations downstream of this alteration have been reported in the literature as disease-causing in PCM (26-28). Based on the currently available information, both compound heterozygous frameshift variants have been classified as pathogenic variants. </P>

<P>LRP1B: NM_018557.3(LRP1B):c.5812A&gt;C p.(Lys1938Gln) A missense variant (c.5812A&gt;C) in exon 36 that results in the alteration of the codon at amino acid position 1938 from lysine to glutamine p. (Lys1938Gln) was detected in this tumor specimen. LRP1B encodes low-density lipoprotein receptor-related protein 1b, a putative tumor suppressor that belongs to the low-density lipoprotein (LDL) receptor family (29). Pathogenic LRP1B alterations may be associated with tumor mutational burden and improved outcomes following immune checkpoint inhibitor therapy in some solid tumors (30,31). LRP1B is one of the most frequently mutated genes in plasma cell myeloma (PCM) at diagnosis (~12%) and reported to be associated with adverse outcome (32,33). This variant has not been observed in a large population cohort (gnomADv3.1.2; https://gnomad.broadinstitute.org). The lysine residue at codon 1938 of LRP1B is evolutionarily conserved and the substitution is predicted to be possibly damaging and tolerated by PolyPhen2 and SIFT, respectively. Based on the currently available information, this variant has been classified as a variant of uncertain clinical significance. </P>
</Sect>

<Sect>
<H6>References </H6>

<L>
<LI>
<Lbl>1. </Lbl>

<LBody>Daugherty, M., Polanuyer, B., Farrell, M., Scholle, M., Lykidis, A., de Crecy-Lagard, V., Osterman, A. Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. J. Biol. Chem. 277:21431-21439, 2002. PMID: 11923312. </LBody>
</LI>

<LI>
<Lbl>2. </Lbl>

<LBody>W J Chng, R Santana-Davila, S A Van Wier, G J Ahmann, S M Jalal, P L Bergsagel, M Chesi, M C Trendle, S Jacobus, E Blood, M M Oken, KHenderson, R A Kyle, M A Gertz, M Q Lacy, A Dispenzieri, P R Greipp & R Fonseca. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 20, 807–813 (2006). https://doi.org/10.1038/sj.leu.2404172. PMID: 16511510. </LBody>
</LI>

<LI>
<Lbl>3. </Lbl>

<LBody>Yang N, Mun YC, Seong CM, Huh HJ, Huh J. Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. Ann Lab Med. 2018 Mar;38(2):160-164. doi: 10.3343/alm.2018.38.2.160. PMID: 29214761. </LBody>
</LI>

<LI>
<Lbl>4. </Lbl>

<LBody>Paola E. Leone, Brian A. Walker, Matthew W. Jenner, Laura Chiecchio, GianPaolo Dagrada, Rebecca K.M. Protheroe, David C. Johnson, Nicholas J. Dickens, Jose Luis Brito, Monica Else, David Gonzalez, Fiona M. Ross, Selina Chen-Kiang, Faith E. Davies, and Gareth J. Morgan. Deletions of CDKN2C </LBody>
</LI>
</L>

<P>IU Diagnostic Genomics Laboratory</P>

<P>in Multiple Myeloma: Biological and Clinical Implications. Clin Cancer Res. 2008 Oct 1; 14(19): 6033–6041. doi: 10.1158/1078-0432.CCR-08-0347. PMID: 18829482. </P>

<L>
<LI>
<Lbl>5. </Lbl>

<LBody>Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J., Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303. doi: 10.1182/blood-2005-01-0034. PMID: 15755896. </LBody>
</LI>

<LI>
<Lbl>6. </Lbl>

<LBody>Walker, B.A.; Mavrommatis, K.; Wardell, C.P.; Ashby, T.C.; Bauer, M.; Davies, F.; Rosenthal, A.; Wang, H.; Qu, P.; Hoering, A.; et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2019, 33, 159–170. doi: 10.1038/s41375-018-0196-8. PMID: 29967379. </LBody>
</LI>

<LI>
<Lbl>7. </Lbl>

<LBody>Walker, B.A.; Boyle, E.M.; Wardell, C.P.; Murison, A.; Begum, D.B.; Dahir, N.M.; Proszek, P.Z.; Johnson, D.C.; Kaiser, M.F.; Melchor, L.; et al. Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma. J. Clin. Oncol. 2015, 33, 3911–3920. doi: 10.1200/JCO.2014.59.1503. PMID: 26282654. </LBody>
</LI>

<LI>
<Lbl>8. </Lbl>

<LBody>Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019;54:353–367. https://doi.org/10.1038/s41409-018-0264-8. PMID: 29988062. </LBody>
</LI>

<LI>
<Lbl>9. </Lbl>

<LBody>Hao, S., Lu, X., Gong, Z. et al. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Mod Pathol 34, 327–335 (2021). https://doi.org/10.1038/s41379-020-00669-7. PMID: 32908255. </LBody>
</LI>

<LI>
<Lbl>10. </Lbl>

<LBody>Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, Lonial S; MMRF CoMMpass Network, Russell SJ, Stewart AK. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J. 2017 Sep 22;7(9):e612. doi: 10.1038/bcj.2017.94. PMID: 28937974. </LBody>
</LI>

<LI>
<Lbl>11. </Lbl>

<LBody>Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03840132. Epub 2018 Jun 8. Erratum in: Blood. 2018 Sep 27;132(13):1461. PMID: 29884741. </LBody>
</LI>

<LI>
<Lbl>12. </Lbl>

<LBody>Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget. 2017 Apr 25;8(17):27854-27867. doi: 10.18632/oncotarget.15718. PMID:28427158. </LBody>
</LI>

<LI>
<Lbl>13. </Lbl>

<LBody>Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun MH, Hsu CC, Wang L, Fitzsimons E, Salminen O, Blaney P, Czader M, Williams J, Abu Zaid MI, Ansari-Pour N, Yong KL, van Rhee F, Pierceall WE, Morgan GJ, Flynt E, Gooding S, Abonour R, Ramasamy K, Thakurta A, Walker BA. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma. Clin Cancer Res. 2022 Jul 1;28(13):2854-2864. doi: 10.1158/1078-0432.CCR-21-3695. PMID: 35522533. </LBody>
</LI>

<LI>
<Lbl>14. </Lbl>

<LBody>Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682-9.PMID: 2547513. </LBody>
</LI>

<LI>
<Lbl>15. </Lbl>

<LBody>Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Baldini L, Neri A. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget. 2015 Sep 15;6(27):24205-17. doi:10.18632/oncotarget.4434. PMID: 26090869. </LBody>
</LI>

<LI>
<Lbl>16. </Lbl>

<LBody>Kortüm KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. Br J Haematol. 2015 Feb;168(4):507-10. doi:10.1111/bjh.13171. PMID:25302557. </LBody>
</LI>

<LI>
<Lbl>17. </Lbl>

<LBody>White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J. 2018 Mar 21;8(3):35. doi:10.1038/s41408-018-0062-y. PMID: 29563506. </LBody>
</LI>

<LI>
<Lbl>18. </Lbl>

<LBody>Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014 Jan 30;123(5):632-9. doi:10.1182/blood-2013-05-504340. PMID: 24335104. </LBody>
</LI>

<LI>
<Lbl>19. </Lbl>

<LBody>Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008 Oct 1;14(19):6033-41. doi:10.1158/1078-0432.CCR-08-0347. PMID: 18829482. </LBody>
</LI>

<LI>
<Lbl>20. </Lbl>

<LBody>Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J. 2017 Feb 24;7(2):e535. doi:10.1038/bcj.2017.12. PMID: 28234347. </LBody>
</LI>

<LI>
<Lbl>21. </Lbl>

<LBody>Dib A, Peterson TR, Raducha-Grace L, Zingone A, Zhan F, Hanamura I, Barlogie B, Shaughnessy J Jr, Kuehl WM. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression. Cell Div. 2006 Oct 18;1:23. doi:10.1186/1747-1028-1-23. PMID: 17049078. </LBody>
</LI>

<LI>
<Lbl>22. </Lbl>

<LBody>Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. PMID: 28481359. </LBody>
</LI>

<LI>
<Lbl>23. </Lbl>

<LBody>Mroczek S, Chlebowska J, Kuli?ski TM, Gewartowska O, Gruchota J, Cysewski D, Liudkovska V, Borsuk E, Nowis D, Dziembowski A. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Nat Commun. 2017 Sep 20;8(1):619. doi:10.1038/s41467017-00578-5. PMID: 28931820. </LBody>
</LI>

<LI>
<Lbl>24. </Lbl>

<LBody>Zhu YX, Shi CX, Bruins LA, Jedlowski P, Wang X, Kortüm KM, Luo M, Ahmann JM, Braggio E, Stewart AK. Loss of FAM46C Promotes Cell Survival in Myeloma. Cancer Res. 2017 Aug 15;77(16):4317-4327. doi:10.1158/0008-5472.CAN-16-3011. PMID: 28619709. </LBody>
</LI>

<LI>
<Lbl>25. </Lbl>

<LBody>Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011 Dec 15;17(24):7776-84. doi: 10.1158/1078-0432.CCR-11-1791. PMID: 21994415. </LBody>
</LI>

<LI>
<Lbl>26. </Lbl>

<LBody>Barbieri M, Manzoni M, Fabris S, Ciceri G, Todoerti K, Simeon V, Musto P, Cortelezzi A, Baldini L, Neri A, Lionetti M. Compendium of FAM46C gene mutations in plasma cell dyscrasias. Br J Haematol. 2016 Aug;174(4):642-5. doi:10.1111/bjh.13793. PMID: 26456599. </LBody>
</LI>

<LI>
<Lbl>27. </Lbl>

<LBody>White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, </LBody>
</LI>
</L>

<P>IU Diagnostic Genomics Laboratory</P>

<P>DiPersio JF, Levy J, Auclair D, Tomasson MH. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J. 2018 Mar 21;8(3):35. doi:10.1038/s41408-018-0062-y. PMID: 29563506. </P>

<L>
<LI>
<Lbl>28. </Lbl>

<LBody>Tessoulin B, Moreau-Aubry A, Descamps G, Gomez-Bougie P, Maïga S, Gaignard A, Chiron D, Ménoret E, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. J Hematol Oncol. 2018 Dec 13;11(1):137. doi:10.1186/s13045-018-0679-0. PMID: 30545397. </LBody>
</LI>

<LI>
<Lbl>29. </Lbl>

<LBody>Liu CX, Li Y, Obermoeller-McCormick LM, Schwartz AL, Bu G. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J Biol Chem. 2001 Aug 3;276(31):28889-96. doi:10.1074/jbc.M102727200. PMID: 11384978. </LBody>
</LI>

<LI>
<Lbl>30. </Lbl>

<LBody>Chen H, Chong W, Wu Q, Yao Y, Mao M, Wang X. Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Front Immunol. 2019 May 21;10:1113. doi:10.3389/fimmu.2019.01113. PMID: 31164891. </LBody>
</LI>

<LI>
<Lbl>31. </Lbl>

<LBody>Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, Labriola MK, Gupta RT, Marin D, Wu Y, Gupta S, Zhang T, Harrison MR, George DJ, Alva A, Antonarakis ES, Armstrong AJ. LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types. J Immunother Cancer. 2021 Mar;9(3):e001792. doi:10.1136/jitc-2020-001792. PMID: 33653800. </LBody>
</LI>

<LI>
<Lbl>32. </Lbl>

<LBody>Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, Munshi N, Avet-Loiseau H. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018 Dec;32(12):2636-2647. doi: 10.1038/s41375-018-0153-6. PMID: 29895955. </LBody>
</LI>

<LI>
<Lbl>33. </Lbl>

<LBody>Cody Ashby, Eileen Boyle, Ruslana G. Tytarenko, Hongwei Wang, Adam Rosenthal, Purvi Patel, Yan Wang, Shayu Deshpande, Maria Ortiz, Erin Flynt, Antje Hoering, Sharmilan Thanendrarajan, Carolina D. Schinke, Maurizio Zangari, Frits van Rhee, Bart Barlogie, Anjan Thakurta, Gareth Morgan, Brian A Walker; Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma. Blood 2018; 132 (Supplement 1): 110. doi:10.1182/blood-2018-99-113045. </LBody>
</LI>
</L>
</Sect>
</Sect>

<Sect>
<H6>ASSAY INFORMATION </H6>

<P>Plasma Cell Myeloma (PCM) is the most common primary bone malignancy due to a neoplastic proliferation of monoclonal plasma cells within the bone marrow. The mutational spectrum for PCM has a broad range of driver genes that are recurrently mutated. These include MAPK/ERK pathway mutations in KRAS (22%), NRAS (18%), and BRAF (8%), as well as the NF-κB pathway mutations in TRAF2 (3%), TRAF3 (6%), CYLD (4%), NFKB2 (1%), and NFKBIA (2%). Other frequently mutated genes include TENT5C (9%), DIS3 (10%), and TP53 (6%). The PCM panel includes 224 genes previously published and frequently mutated genes, 56 loci for copy number variation, and 6 loci for detecting recurrent immunoglobulin and MYC translocations. The PCM panel can detect translocations involving the IGH, IGK, IGL and MYC loci, as well as relevant copy number abnormalities (del(1p), gain/amp(1q), del(13q), del(17p), and hyperdiploidy), single nucleotide variants such as base substitutions and small insertions and deletions. The panel has additional probes at known polymorphic SNPs to aid with copy number determination and detect copy number neutral loss of heterozygosity. </P>

<P>Note: A full gene list is provided at the end of this report. </P>
</Sect>

<Sect>
<H6 id="LinkTarget_100">Method </H6>

<P>The panel is based on SeqCap technology (Cheng et al. J Mol Diagn. 2015;17(3):251-64). Briefly, 100 ng DNA from both non-tumor (PBSC or saliva) and CD138+ sorted tumor cells (purity of approximately 80% or higher) undergo enzymatic fragmentation, end-repair, A-tailing, and index adapter ligation (HyperPlus kit, Roche), before being amplified. Amplified fragments are hybridized overnight to DNA probes (Roche) for enrichment of regions of interest, cleaned, and amplified again before being sequenced using 150 bp paired end reads on an Illumina sequencer (NovaSeq 6000). Generated sequencing data are aligned to the human reference genome (GRCh38). Variants are called based on paired analysis using the submitted patient’s CD138+ sorted tumor and the match non-tumor samples. Unless specified, all targeted exons have minimum depth of coverage of 100X. </P>
</Sect>

<Sect>
<H6 id="LinkTarget_101">Limitations: </H6>

<P>Only variants within the targeted genomic regions will be detected. Variants outside the targeted genomic regions will not be detected. Variants that have VAF &lt;5% may not be detected. Tumor content greatly affects the ability to detect copy number changes in samples with less than 20% tumor. For samples with low tumor content, the absence of detectable copy number changes should be interpreted with caution. All results should be interpreted in context of clinical findings, relevant history, and other laboratory data. </P>
</Sect>

<Sect>
<H6 id="LinkTarget_102">Disclaimer: </H6>

<P>This test was developed, and its performance characteristics determined by Indiana University Diagnostic Genomics Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. The laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88) as qualified to perform high complexity clinical laboratory testing. </P>

<P>IU Diagnostic Genomics Laboratory</P>
</Sect>

<Sect>
<H6 id="LinkTarget_103">Plasma Cell Myeloma Gene Sequencing Panel </H6>

<Table>
<TR>
<TD>ABCD4 </TD>

<TD>BRF1 </TD>

<TD>DNAH5 </TD>

<TD>GPC5 </TD>

<TD>KLHL6 </TD>

<TD>NFKBIA </TD>

<TD>PSMB4 </TD>

<TD>TAF1 </TD>
</TR>

<TR>
<TD>ABCF1 </TD>

<TD>BTG1 </TD>

<TD>DNMT3A </TD>

<TD>HDAC1 </TD>

<TD>KMT2B </TD>

<TD>NOTCH1 </TD>

<TD>PSMB6 </TD>

<TD>TBX15 </TD>
</TR>

<TR>
<TD>ACTG1 </TD>

<TD>C8orf34 </TD>

<TD>DOCK5 </TD>

<TD>HDAC4 </TD>

<TD>KMT2C </TD>

<TD>NOTCH3 </TD>

<TD>PSMB7 </TD>

<TD>TCL1A </TD>
</TR>

<TR>
<TD>ADAM29 </TD>

<TD>CARD11 </TD>

<TD>DOT1L </TD>

<TD>HDAC7 </TD>

<TD>KMT2D </TD>

<TD>NOTCH4 </TD>

<TD>PSMB8 </TD>

<TD>TDG </TD>
</TR>

<TR>
<TD>ADCY2 </TD>

<TD>CCND1 </TD>

<TD>DPYD </TD>

<TD>HIST1H1C </TD>

<TD>KRAS </TD>

<TD>NPM1 </TD>

<TD>PSMD1 </TD>

<TD>TET1 </TD>
</TR>

<TR>
<TD>AKAP1 </TD>

<TD>CCND3 </TD>

<TD>DUSP2 </TD>

<TD>HIST1H1D </TD>

<TD>LRP1B </TD>

<TD>NR3C1 </TD>

<TD>PSMG2 </TD>

<TD>TET2 </TD>
</TR>

<TR>
<TD>ARHGEF12 </TD>

<TD>CD36 </TD>

<TD>DUOX2 </TD>

<TD>HIST1H1E </TD>

<TD>LRRK2 </TD>

<TD>NRAS </TD>

<TD>PSPC1 </TD>

<TD>TET3 </TD>
</TR>

<TR>
<TD>ARID1A </TD>

<TD>CD79A </TD>

<TD>EGFR </TD>

<TD>HLA-A </TD>

<TD>LTB </TD>

<TD>PABPC1 </TD>

<TD>PTEN </TD>

<TD>TGDS </TD>
</TR>

<TR>
<TD>ARID2 </TD>

<TD>CDK4 </TD>

<TD>EGR1 </TD>

<TD>HLA-B </TD>

<TD>MAF </TD>

<TD>PANK3 </TD>

<TD>PTPN11 </TD>

<TD>TIAM2 </TD>
</TR>

<TR>
<TD>ASAP2 </TD>

<TD>CDKN1B </TD>

<TD>EP300 </TD>

<TD>HLA-C </TD>

<TD>MAFB </TD>

<TD>PARK2 </TD>

<TD>PTPRD </TD>

<TD>TLR4 </TD>
</TR>

<TR>
<TD>ASXL1 </TD>

<TD>CDKN2A </TD>

<TD>EPHA3 </TD>

<TD>HUWE1 </TD>

<TD>MAML2 </TD>

<TD>PCLO </TD>

<TD>RAD50 </TD>

<TD>TP53 </TD>
</TR>

<TR>
<TD>ATM </TD>

<TD>CDKN2B </TD>

<TD>ETV6 </TD>

<TD>IDH1 </TD>

<TD>MAML3 </TD>

<TD>PEG3 </TD>

<TD>RAG2 </TD>

<TD>TRAF2 </TD>
</TR>

<TR>
<TD>ATP13A4 </TD>

<TD>DKN2C </TD>

<TD>EVI5 </TD>

<TD>IDH2 </TD>

<TD>MAN2C1 </TD>

<TD>PIGO </TD>

<TD>RASA2 </TD>

<TD>TRAF3 </TD>
</TR>

<TR>
<TD>ATR </TD>

<TD>CHD1 </TD>

<TD>EZH1 </TD>

<TD>IGF1R </TD>

<TD>MAP3K1 </TD>

<TD>PIK3CA </TD>

<TD>RB1 </TD>

<TD>TSHZ3 </TD>
</TR>

<TR>
<TD>ATRX </TD>

<TD>CHD2 </TD>

<TD>EZH2 </TD>

<TD>IKZF1 </TD>

<TD>MAP3K14 </TD>

<TD>PIM1 </TD>

<TD>RBX1 </TD>

<TD>U2AF1 </TD>
</TR>

<TR>
<TD>BCL10 </TD>

<TD>CHD4 </TD>

<TD>FAF1 </TD>

<TD>IKZF3 </TD>

<TD>MAST4 </TD>

<TD>PIM3 </TD>

<TD>RFTN1 </TD>

<TD>UBR5 </TD>
</TR>

<TR>
<TD>BCL6 </TD>

<TD>CHEK1 </TD>

<TD>TENT5C </TD>

<TD>IKZF4 </TD>

<TD>MAX </TD>

<TD>PKHD1 </TD>

<TD>ROBO1 </TD>

<TD>USP29 </TD>
</TR>

<TR>
<TD>BCL7A </TD>

<TD>CHEK2 </TD>

<TD>FANCA </TD>

<TD>IL6ST </TD>

<TD>MCL1 </TD>

<TD>PLCE1 </TD>

<TD>RPL5 </TD>

<TD>USP7 </TD>
</TR>

<TR>
<TD>BCL9 </TD>

<TD>CKS1B </TD>

<TD>FANCD2 </TD>

<TD>IRF4 </TD>

<TD>MKI67 </TD>

<TD>POT1 </TD>

<TD>RPS3A </TD>

<TD>WHSC1 </TD>
</TR>

<TR>
<TD>BCORL1 </TD>

<TD>CRBN </TD>

<TD>FANCI </TD>

<TD>JAK1 </TD>

<TD>MLL </TD>

<TD>PRDM1 </TD>

<TD>SAMHD1 </TD>

<TD>WHSC1L1 </TD>
</TR>

<TR>
<TD>BIRC2 </TD>

<TD>CREBBP </TD>

<TD>FANCM </TD>

<TD>JAK2 </TD>

<TD>MYC </TD>

<TD>PRDM9 </TD>

<TD>SETD2 </TD>

<TD>WWOX </TD>
</TR>

<TR>
<TD>BIRC3 </TD>

<TD>CUL4A </TD>

<TD>FAT1 </TD>

<TD>JAK3 </TD>

<TD>MYD88 </TD>

<TD>PRKD2 </TD>

<TD>SF3B1 </TD>

<TD>XBP1 </TD>
</TR>

<TR>
<TD>BIRC5 </TD>

<TD>CUL4B </TD>

<TD>FAT4 </TD>

<TD>KAT6A </TD>

<TD>NCKAP5 </TD>

<TD>PRMT5 </TD>

<TD>SHC1 </TD>

<TD>XPO1 </TD>
</TR>

<TR>
<TD>BMP2K </TD>

<TD>CXCR4 </TD>

<TD>FBXW7 </TD>

<TD>KDM2B </TD>

<TD>NCOR1 </TD>

<TD>PSMB1 </TD>

<TD>SMARCA4 </TD>

<TD>ZFHX3 </TD>
</TR>

<TR>
<TD>BRAF </TD>

<TD>CYLD </TD>

<TD>FCHSD2 </TD>

<TD>KDM3B </TD>

<TD>NEDD9 </TD>

<TD>PSMB10 </TD>

<TD>SNX7 </TD>

<TD>ZFHX4 </TD>
</TR>

<TR>
<TD>BRCA1 </TD>

<TD>DDB1 </TD>

<TD>FGFR3 </TD>

<TD>KDM5A </TD>

<TD>NF1 </TD>

<TD>PSMB11 </TD>

<TD>SP140 </TD>

<TD>ZFP36L1 </TD>
</TR>

<TR>
<TD>BRCA2 </TD>

<TD>DDX3X </TD>

<TD>FLT3 </TD>

<TD>KDM5C </TD>

<TD>NFKB1 </TD>

<TD>PSMB2 </TD>

<TD>SPEN </TD>

<TD>ZNF292 </TD>
</TR>

<TR>
<TD>BRD4 </TD>

<TD>DIS3 </TD>

<TD>FUBP1 </TD>

<TD>KDM6A </TD>

<TD>NFKB2 </TD>

<TD>PSMB3 </TD>

<TD>STAT3 </TD>

<TD>ZRSR2 </TD>
</TR>
</Table>
</Sect>

<Sect>
<H6 id="LinkTarget_104">Copy number variants </H6>

<Table>
<TR>
<TH>SN </TH>

<TH>Loci </TH>

<TH>SN </TH>

<TH>Loci </TH>
</TR>

<TR>
<TD>1 </TD>

<TD>1pCEN_CN </TD>

<TD>6 </TD>

<TD>CKS1B </TD>
</TR>

<TR>
<TD>2 </TD>

<TD>CDKN2C_CN </TD>

<TD>7 </TD>

<TD>13qCEN_CN </TD>
</TR>

<TR>
<TD>3 </TD>

<TD>1pTEL_CN </TD>

<TD>8 </TD>

<TD>13qTEL_CN </TD>
</TR>

<TR>
<TD>4 </TD>

<TD>1q21.3_CN </TD>

<TD>9 </TD>

<TD>RB1_CN </TD>
</TR>

<TR>
<TD>5 </TD>

<TD>1qTEL_CN </TD>

<TD>10 </TD>

<TD>TP53_CN </TD>
</TR>
</Table>
</Sect>

<Sect>
<H6 id="LinkTarget_105">Translocations </H6>

<Table>
<TR>
<TH/>

<TH>SN </TH>

<TH/>

<TH>Genes </TH>

<TH/>

<TH>SN </TH>

<TH/>

<TH>Genes </TH>
</TR>

<TR>
<TD>1 </TD>

<TD/>

<TD>IGK </TD>

<TD/>

<TD>4 </TD>

<TD/>

<TD>IGH </TD>

<TD/>
</TR>

<TR>
<TD>2 </TD>

<TD/>

<TD>MYC </TD>

<TD/>

<TD>5 </TD>

<TD/>

<TD>IGL </TD>

<TD/>
</TR>
</Table>

<P>IU Diagnostic Genomics Laboratory</P>
</Sect>
</Sect>

<Sect>
<H5>Fankhauser, Cynthia 03/10/2023 Page 5 of 6 </H5>

<Sect>
<H6>ELECTRONICALLY SIGNED BY </H6>
</Sect>
</Sect>

<Sect>
<H5>Francesco Vetrini, Ph.D., FACMG, Associate Director, Diagnostic Genomics laboratory, Assistant Director, Cytogenetics Laboratories, 03/10/2023 </H5>
<Figure>

<ImageData src="images/RPT28095_img_1.jpg"/>
</Figure>

<P>IU Diagnostic Genomics Laboratory</P>
</Sect>
</Part>
</TaggedPDF-doc>
